Morgan Stanley raised its price target on Broadcom to $505 this week, up from $502, citing surging AI chip demand and what the bank sees as bold revenue growth targets from CEO Hock Tan. The Street has the details if you want the full write-up. I'd remind everyone, gently, that stars and price targets have a way of going dark at the same time.

None of this surprises me. Broadcom sits right in the middle of the AI build-out, and to be clear I'm going on general industry knowledge here rather than the analyst note itself, but when AI spending is the story of the moment, analysts raise targets on the companies closest to it. Practically a reflex.

The number itself, $505, deserves a reality check. A price target is one firm's guess about where a stock might trade in twelve months, built on assumptions about revenue growth, margins, and a multiple someone thinks is reasonable. Nudge any one of those assumptions slightly and the target moves by fifty dollars. I've watched these targets get raised all the way up and lowered all the way down, usually in tidy sequence with the stock itself. Analysts follow prices more often than they lead them.

That's not a knock on Morgan Stanley specifically. The reasoning is sound on its face. AI demand is real, Hock Tan has a long history of buying businesses and squeezing better economics out of them, and if the AI capex cycle keeps running, Broadcom is positioned to be one of the clearer beneficiaries.

But the question a regular investor should ask has less to do with whether the target is right, and more to do with whether you'd be comfortable owning the stock if the cycle turns before the target date arrives. Semiconductor demand is cyclical even when the narrative says it isn't. As general market history, offered as context rather than a precise statistic, the dot-com era taught us that a real technology trend and a well-timed stock purchase are two different things. The internet was real. Plenty of prices were early.

If you already own Broadcom through a broad index fund, and most of you do, you got a small lift from this news without lifting a finger. That's the boring approach doing its job quietly. If you're thinking of buying it directly because an analyst moved a number, size it like a bet, because that's what a single stock always is. I've said before that one stock is a bet, not a plan, and a $505 target doesn't change that.

Patient money doesn't need the target to be exactly right. It just needs the decades to be roughly right.

As always, this is my perspective, not professional financial advice. Do your own homework or talk to a fiduciary before you act on any of it.